Merck & Co., Inc: Neoplasm Metastasis trials
The registry lists 22 Neoplasm Metastasis studies with Merck & Co., Inc as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 15Phase 2 8Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)RecruitingNCT07030712Phase 1
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingNCT06863272Phase 1/2
- A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)TerminatedNCT04521621Phase 1/2Results posted
- Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)CompletedNCT04220866Phase 2Results posted
- A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)TerminatedNCT04135352Phase 1Results posted
- Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)CompletedNCT03745989Phase 1Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results posted
- Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)TerminatedNCT00931606Phase 2Results posted
- A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)CompletedNCT00874731Phase 1Results posted
- A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)CompletedNCT06460961Phase 1
- A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)WithdrawnNCT06395090Phase 1/2
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active, not recruitingNCT04895358Phase 3
- A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active, not recruitingNCT02974738Phase 1
- Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)CompletedNCT01071304Phase 1
- Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic MalignanciesCompletedNCT00825487Phase 1
- ARQ 197 in Subjects With Metastatic Solid TumorsCompletedNCT00302172Phase 1
- Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)CompletedNCT00112372Phase 1
- Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)CompletedNCT00093080Phase 2
- Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)CompletedNCT00076856Phase 2
- Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)TerminatedNCT00050336Phase 3
- Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)TerminatedNCT00034697Phase 2
- SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)CompletedNCT00002960Phase 1